Reem Mahrat recognized for advancing AI-enabled biomarker testing

Influential Women has recognized biotechnology entrepreneur Reem Mahrat for work on at-home and point-of-care biomarker testing powered by AI. The recognition highlights EazeBio’s push to make biological information more accessible for patients, with commercial launch planned for 2026.

Why it matters: - Reem Mahrat is building tools meant to give patients earlier, clearer information about changes in their biology. - EazeBio aims to move biomarker testing out of the lab and into home and point-of-care settings. - The platform is designed to help people track trends over time, not just single test results. - The approach could support earlier conversations with clinicians and more informed care decisions.

What happened: - Influential Women recognized Reem Mahrat for work at the intersection of diagnostics, artificial intelligence and patient-centered healthcare. - Mahrat is the Founder and CEO of EazeBio, a biotechnology company developing AI-enabled biomarker testing for at-home and point-of-care use. - Mahrat is a chemical engineer, published scientist, author and clinical research leader. - Mahrat has spent more than two decades working in diagnostics, therapeutics and precision medicine. - Mahrat is a four-time founder with three exits: RamanID, Calico Bio Labs and Mariposa. - Mahrat is the named inventor on more than 13 patents and applications spanning diagnostics and therapeutics.

The details: - EazeBio is developing a real-time biological intelligence platform that combines biomarker testing, smartphone-based reading and artificial intelligence. - The planned portfolio includes tests for inflammation, hormones, immunity, stress and metabolic health. - EazeBio says the first at-home test for GDF-15 is part of the planned portfolio. - EazeBio is preparing for commercial launch in 2026. - The company is advancing partner-led pilot programs in women’s wellness, metabolic health and stress-related biology. - Additional research applications are underway in oncology and mental health. - The pilot programs are intended to validate performance, refine the user experience and expand the signals the platform can support. - Mahrat’s mission grew out of her own experience of having symptoms that did not match laboratory results described as normal. - Mahrat says that experience shaped her belief that patients should have useful information to participate in informed conversations with clinicians. - Mahrat’s team published an ultrasensitive at-home cortisol assay in the peer-reviewed Journal of Fluorescence in 2026. - The assay is a first-of-its-kind lateral-flow fluorescence sandwich test built on de novo-designed proteins from the 2024 Nobel Prize-winning laboratory of David Baker. - Mahrat has engineered antibodies herself and remains a hands-on scientist. - Mahrat also serves as a SPARK Advisor at Stanford University and as an Entrepreneur in Residence at Daybreak Labs. - Her work centers on decentralized diagnostics, preventive health and technologies that bring biological information closer to the patient. - Mahrat is the author of three books: Feed Your Good Genes, Second Spring and Third Bloom. - The books focus on biology, hormones and long-term wellness. - Mahrat also draws on her experience living with autoimmune disease to help readers better understand and discuss their health.

Between the lines: - The recognition underscores growing interest in diagnostics that combine at-home testing with software-driven interpretation. - EazeBio’s focus on women’s health, metabolic health and stress biology signals a broader push to address conditions that often rely on delayed or fragmented data. - Mahrat is framing patient access to data as a scientific and cultural issue, not just a product issue. - Her emphasis on women’s biology reflects a critique that biotechnology has long relied on incomplete reference points. - The company’s use of Nobel-linked protein design and peer-reviewed assay development is meant to bolster credibility around the technology.

What's next: - EazeBio is preparing for a 2026 commercial launch. - The company plans to keep validating the platform through pilot programs and research applications. - Mahrat says the broader goal is a healthcare model where technology expands access to meaningful biological information and patients have a stronger voice in care. - More information is available through Mahrat’s Influential Women profile and her EazeBio profile.

The bottom line: - Mahrat’s recognition puts a spotlight on a growing category of consumer-facing diagnostics: AI-enabled biomarker testing designed to make biological data easier to access, interpret and use.